KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Assets Average (2022 - 2026)

Takeda Pharmaceutical has reported Assets Average over the past 5 years, most recently at $209.7 billion for Q1 2026.

  • For Q1 2026, Assets Average fell 21.79% year-over-year to $209.7 billion; the TTM value through Mar 2026 reached $209.7 billion, down 21.79%, while the annual FY2026 figure was $98.1 billion, 0.36% changed from the prior year.
  • Assets Average was $209.7 billion for Q1 2026 at Takeda Pharmaceutical, up from $207.1 billion in the prior quarter.
  • Across five years, Assets Average topped out at $468.5 billion in Q1 2023 and bottomed at $207.1 billion in Q4 2025.
  • The 5-year median for Assets Average is $354.4 billion (2025), against an average of $340.8 billion.
  • Year-over-year, Assets Average grew 6.33% in 2023 and then crashed 40.52% in 2025.
  • Over 5 years, Assets Average stood at $440.7 billion in 2022, then rose by 6.33% to $468.5 billion in 2023, then dropped by 3.8% to $450.8 billion in 2024, then plummeted by 54.05% to $207.1 billion in 2025, then increased by 1.24% to $209.7 billion in 2026.
  • The last three reported values for Assets Average were $209.7 billion (Q1 2026), $207.1 billion (Q4 2025), and $268.1 billion (Q1 2025) per Business Quant data.